Company Information
GCLC matured NK cell-based platforms so that Phase I clinical trial was completed in 2012 in Korea while its manufacturing facility is fully compliant with Korean FDA’s GMP guideline. Current MG4101, ex vivo-expanded allogenic NK cell, is on the way of Phase II trial for the patients with HCC. It expanded a clinical indication for the patients with Lymphoma (NHL). Phase 1/2a trial is on-going to evaluate the synergistic effects of an antibody combination therapy. Both trials will be completed in 2020. The NK (cord blood derived) and antibody combination therapy will also be developed in US first in collaboration with Artiva Biotherapeutics located in San Diego in US. The lead clinical trial will start this year and expand to other clinical trials with various antibody combinations the following year. Also, GCLC and Artiva have also been collaborating CAR-NK programs to initiate clinical trials.
